Magnetic resonance (MRI)-based molecular imaging methods are beginning to have impact in neuroscience. A growing number of molecular imaging agents have been synthesized and tested in vitro, but so far relatively few have been validated in the brains of live animals. Here, we discuss key challenges associated with expanding the repertoire of successful molecular neuroimaging approaches. The difficulty of delivering agents past the blood-brain barrier (BBB) is a particular obstacle to molecular imaging in the central nervous system. We review established and emerging techniques for trans-BBB delivery, including intracranial infusion, BBB disruption, and transporterrelated methods. Improving the sensitivity with which MRI-based molecular agents can be detected is a second major challenge. Better sensitivity would in turn reduce the requirements for delivery and alleviate potential side effects. We discuss recent efforts to enhance relaxivity of conventional longitudinal relaxation time (T 1 ) and transverse relaxation time (T 2 ) MRI contrast agents, as well as strategies that involve amplifying molecular signals or reducing endogenous background influences. With ongoing refinement of imaging approaches and brain delivery methods, MRI-based techniques for molecular-level neuroscientific investigation will fall increasingly within reach.
I. INTRODUCTION
Molecular imaging agents have the potential to transform our understanding of brain physiology and function. Discovery of the hemoglobin-mediated blood oxygenation level dependent (BOLD) effect on magnetic resonance imaging (MRI) signal (Ogawa et al., 1990) and the mapping of radiolabeled tracer distribution using positron emission tomography (PET) (Phelps et al., 1975) have already had tremendous impact in both basic and clinical neuroscience. Despite these pioneering advances, it is not yet possible to use MRI-and PETbased approaches to answer arbitrary questions about molecular processes underlying brain function, largely because of limitations inherent in the physics of the imaging methods and probes themselves. Although PET methods can detect femtomolar levels of β-emitting compounds, resolution is usually limited to several millimeters, and studies of dynamic processes are only possible where significant redistribution of probes takes place. With MRI, a wide array of contrast mechanisms is available, and spatial and temporal resolution are typically more than an order of magnitude better than PET. On the other hand, the sensitivity of MRI for existing molecular probes is relatively poor, and innovations in probe design and related in vivo methods are highly desirable.
Most molecular imaging agents for MRI have been developed over the past 10 years. Specific imaging agents have been created to target epitopes, track small molecules, measure changes in pH and ion concentrations, respond to enzymes, and report changes in gene expression. Most of the agents fall into four classes, based on the MRI contrast mechanisms they engage: (1) longitudinal relaxation time (T 1 ) agents, detected by T 1 relaxation-weighted MRI (Lauffer, 1987; Toth et al., 2001) ; (2) transverse relaxation time (T 2 ) agents, usually based on superparamagnetic iron oxide (SPIO), and detected by T 2 relaxation-weighted MRI (Muller et al., 2001) ; (3) chemical exchange saturation transfer (CEST) agents, monitored by a variant of magnetization transfer imaging (Sherry and Woods, 2008) ; and (4) heteronuclear agents, detected by nuclear magnetic resonance (NMR) signals from nuclei other than protons, most prominently 19 F (Yu et al., 2005a) or hyperpolarized 13 C (Mansson et al., 2006) . Some agents convey information primarily as a function of their spatial distribution, whereas others sense or respond to targets in a manner affecting their NMR behavior (e.g., their relaxivity, the slope of 1/T 1 or 1/T 2 vs. probe concentration). Recent progress in MRI molecular imaging has been extensively reviewed (e.g., de Leon-Rodriguez et al., 2009; Sosnovik and Weissleder, 2007) , and the potential for neuroscience applications has been recognized (Jasanoff, 2007; Meade et al., 2003) . Despite the ingenuity invested in developing new agents, however, few are in wide-spread use for neuroimaging.
II. LESSONS FROM IN VIVO EXPERIMENTS
The difficulties associated with bringing MRI molecular neuroimaging into research practice are apparent when surveying the subset of the experimental strategies that have been validated so far in living brains. In most cases, large concentrations of contrast media are required, generally well over 10 µM. Further, the most successful strategies are those in which molecular imaging agents have been directed at relatively superficial analytes, or where the agents have been able to exploit endogenous mechanisms to reach their targets.
The most broadly applied molecular imaging method in neuroscience is based on injected paramagnetic Mn 2+ ions that appear to accumulate in an activity-dependent manner in the brain by promiscuous uptake through neuronal voltage gated calcium channels (Lin and Koretsky, 1997; Pautler et al., 1998) . Although Mn 2+ -enhanced functional imaging was originally used in conjunction with blood-brain barrier (BBB) disruption (Lin and Koretsky, 1997; Aoki et al., 2002) , subsequent applications have benefited from the fact that Mn 2+ crosses the BBB, and can thus be injected directly into the bloodstream or peritoneum (Lee et al., 2005; Yu et al., 2005b) . The ability to stimulate for long periods of time in the presence of Mn 2+ has been critical to achieving reliable contrast, indicating that fairly high local concentrations of Mn 2+ are necessary for detection . Like Mn 2+ , and also in analogy to PET tracers, 13 C-labeled agents can exploit endogenous uptake mechanisms. Using hyperpolarization methods, the sensitivity with which 13 C compounds are detected can be boosted by many orders of magnitude (Ardenkjaer-Larsen et al., 2003) , though their potential for some brain imaging applications may be hindered by limits on polarization lifetime. In recent in vivo applications, hyperpolarization-based imaging techniques have been applied to follow 13 C-labeled bicarbonate (Gallagher et al., 2008) and metabolites , each of which is associated with established families of transporters and processing enzymes.
Additional recent in vivo successes include agents designed to target relatively accessible physiological markers in the vasculature, and genetically encoded agents that avoid the need for exogenous delivery. Strong SPIO T 2 contrast agents have been designed to bind vascular epitopes indicative of cerebral inflammation Serres et al., 2009 ). Upregulation of selectins on the vascular endothelium is detectable by the agents after intravenous injection (Sibson et al., 2004; Boutry et al., 2005) . High iron concentrations were achieved by using relatively large particles (~80-nm diameter), and because cellular barriers and the BBB did not need to be traversed. Strategies for imaging vascular pH in the brain have also been feasible (Garcia-Martin et al., 2006) , both because transport of pH sensors is not required after intravenous delivery, and because endogenous pH buffering is strong enough for the brain to tolerate large concentrations of contrast agents. Proof of principle experiments with genetically encoded contrast agents circumvented the delivery problem because the agents were biosynthesized endogenously . To achieve adequate sensitivity, the genetic strategies introduced so far have also included a "multiplicative" aspect. Individual ferritin molecules (Genove et al., 2005; Cohen et al., 2007) each accumulate up to 2000 iron atoms per polypeptide 24-mer. MagA iron pumps (Zurkiya et al., 2008; Goldhawk et al., 2009) can presumably promote even larger iron to protein ratios. Individual protein CEST agents of moderate size (Gilad et al., 2007; McMahon et al., 2008) might reasonably provide on the order of 10 3 to 10 4 sites for labile proton exchange. All of these agents have for the most part been tested in contexts where high-level expression, perhaps in the order of 1 µM, is possible.
For the generic MRI molecular imaging agent, which may be highly polar, nanometer sized, or directed toward intracellular targets of exceptional significance, it is clearly not possible to rely on endogenous transport mechanisms for delivery into the brain or into cells. Although in some cases, it may be possible to engineer genetically encoded contrast agents to generate more complex functionality like responsiveness to intracellular signaling (Shapiro et al., 2009) , genetically encoded species are generally less effective contrast agents than synthetic molecules, and of course could only be used in transgenic or transfected animals. For neuroimaging applications involving exogenous agents, efficient artificial delivery techniques are required. To mitigate difficulties associated with delivery, and to reduce potentially adverse effects of agents introduced into the brain, a closely related aim is required to improve MRI contrast agents, so that lower concentrations are required for detection. In the remainder of this review, we discuss critical challenges involved with developing effective strategies for molecular MRI in the brain, focusing particularly on advances in delivery methodology and sensitivity that may be critical to relatively near-term applications of newly developed molecular imaging agents in live animals.
III. STRATEGIES FOR DELIVERY OF MRI CONTRAST AGENTS TO THE BRAIN
Delivery of contrast agents designed for neuroimaging is particularly difficult because of the BBB, a specialized system of tight junctions between vascular endothelial cells and associated astrocytes that protects the brain from the potentially harmful substances in the bloodstream. The BBB restricts transport and diffusion of molecules between the brain and the cerebral vasculature. Only lipophilic molecules with molecular mass smaller than 400 Da are thought to cross the BBB passively by free diffusion (Pardridge, 2003) . Some other types of molecules can transverse the BBB via endogenous active transport systems. The two most common transport processes across the BBB are carrier-mediated transport, for small water-soluble vitamins and nutrients; and receptor-mediated transport for certain large peptides and plasma proteins (Pardridge, 2005) .
Because the BBB prevents brain delivery of diagnostic and therapeutic agents alike, techniques to bypass it have become the subject of extensive research. The best established trans-BBB delivery methods include invasive injection, as well as relatively noninvasive BBB disruption methods (Vykhodtseva et al., 2008) . Intracerebral injection techniques are workhorse methods in neuroscience, both for delivery of imaging agents and for pharmacological treatments. Three protocols are most commonly used: infusion through catheters implanted directly into brain tissue, intracerebroventricular infusion, and convection enhanced delivery (CED) using osmotic pumps or related devices (Pardridge, 2005) . In addition to their invasiveness, the main limitation of these methods is the inhomogeneous and limited spread of molecules emanating from the delivery point. With sustained infusion, it is nevertheless possible to deliver agents to relatively large portions of a rodent brain. The approaches have been used to deliver MRI contrast agents to the brain, for example, the CED method has been employed recently to administer gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA) and dextran-coated SPIO nanoparticles to rat brains (Fig. 1A) . These studies showed that relatively high-infusion rates (1-4 µM) achieved a volume of distribution corresponding to most of the striatum in injected animals.
Techniques for transient, reversible BBB disruption provide a mechanism for more homogeneous delivery of agents from the bloodstream into the brain parenchyma. BBB disruption has been linked to the onset of chronic neurological conditions in human subjects (Hawkins and Davis, 2005 ), but has not been shown to impair cognitive function on a time scale relevant to experimental studies in laboratory animals. The most traditional BBB disruption method is to administer a hyperosmotic shock to tight junctions in the cerebrovascular endothelium (Neuwelt and Rapoport, 1984) . This can be performed by intravascular injection (typically through the carotid artery) of a hypertonic but otherwise inert solution such as 25% mannitol. Disruption following the shock persists for around an hour, during which substances can pass between the brain and bloodstream. Hyperosmotic shock methods are used clinically for treatment of conditions such as intracranial hypertension (Berger et al., 1995) , ischemic stroke (Schwarz et al., 1998) , and delivery of chemotherapeutic agents (Neuwelt et al., 1983) ; complications are noted only in a minority of cases (Elkassabany et al., 2008) . In animals, hyperosmotic disruption of the BBB has been used to deliver Mn 2+ in conjunction with neural activity-dependent labeling studies using MRI. Synthetic MRI contrast agents such as Gd-DTPA (Norman et al., 1991; Roman-Goldstein et al., 1994 ) and a variety of carbohydrate-coated SPIO nanoparticles have been delivered to rodent brains after osmotic BBB disruption using mannitol (Fig. 1B) . The most pronounced contrast changes were ipsilateral to the mannitol infusion, and were more homogeneous for the small molecule agent than for large nanoparticles.
A promising but more exploratory alternative to the hyperosmotic disruption technique uses focused ultrasound (FUS) to open the BBB (Vykhodtseva et al., 2008) . Early studies of FUSdependent BBB disruption found that ultrasonic energy deposition produced collateral damage to surrounding brain tissue (Bakay et al., 1956; Ballantine et al., 1960) . It was later discovered that a sharp reduction in the FUS energy required for BBB opening is possible if gas-filled microbubbles (which act as ultrasound contrast agents) are injected into the bloodstream prior to sonication (Hynynen et al., 2001) . Ultrasound-mediated BBB opening can be performed in MRI scanners and spatially targeted to discrete brain regions on a millimeter scale in rodents, making FUS considerably more versatile than hyperosmotic shock methods. Local BBB disruption with FUS seems to be possible without undesirable long-term effects . A wide variety of molecular species have been delivered to the brain using FUS methods, including Gd-DTPA and ~20-nm diameter SPIO contrast agents for MRI (Fig. 1C ) Liu et al., 2009) , protein therapeutics (Kinoshita et al., 2006) , and small molecules (Hynynen et al., 2005) . Spatiotemporal characteristics of FUS-mediated BBB opening have not been completely characterized, but evidence suggests that the disruption persists for hours, and that larger blood vessels may be most susceptible to sonication (Choi et al., 2007) .
The search for less disruptive strategies for trans-BBB delivery is an active area of research. Reported methods have employed carriers such as liposomes and nanoparticles (Huwyler et al., 1996; Gulyaev et al., 1999) . Additional efforts have focused on "molecular Trojan horse" strategies, in which a substrate for endogenous BBB transport systems is conjugated or fused to the molecule to be delivered, allowing it to be cotransported (Pardridge, 2008) . Molecular Trojan horses include natural and engineered interaction partners targeted to the transferrin and insulin receptors, which have been examined in trial studies for their ability to promote transport of a number of therapeutic proteins and nucleic acids across the BBB (Pardridge, 2007) . Nondisruptive trans-BBB delivery methods have been used in conjunction with a radiopharmaceutical for PET imaging (Lee et al., 2002) and with bacterial β-galactosidase, a reporter used for histological analysis (Zhang and Pardridge, 2005) . Whether these methods can be effectively applied to deliver MRI contrast agents across the BBB is less certain, given the requirement in MRI for high-imaging agent concentrations.
A related Trojan horse approach has proved successful in the delivery of MRI contrast agents into cells through the plasma membrane (Dietz and Bahr, 2004) . For imaging agents designed to sense intracellular targets in the brain, cell delivery is as critical a problem as transduction across the BBB. Both SPIO-based T 2 relaxation agents (Josephson et al., 1999) and small molecule T 1 contrast agents have been reported to enter cells when conjugated to so-called cell penetrating peptides (CPPs), such as polyarginine and the tat peptide from human immunodeficiency virus (Zhao and Weissleder, 2004) . CPP-mediated in vivo delivery of 70-nm fluorescent quantum dot nanoparticles to rat brain tissue (Santra et al., 2004) and cytosolic delivery of polyarginine-conjugated magnetic nanoparticles to implanted tumors in mice (Medarova et al., 2007) have been reported. DNA-facilitated delivery of magnetic nanoparticles in the mouse brain has also been described (Liu et al., 2007 ). An alternative strategy for cell delivery is to design imaging agents using paramagnetic complexes that are intrinsically membrane permeable. Paramagnetic metalloporphyrins have T 1 relaxivity comparable to traditional Gd 3+ -polyaminocarboxylate complexes, and have been modified to form sensors internalized with high efficiency by cells . Further development of agents with biochemical features explicitly conducive to brain or cellular delivery may be an important direction for future MRI molecular neuroimaging research.
IV. NEED FOR IMPROVED DETECTION OF MRI CONTRAST AGENTS
The preceding review of delivery strategies appropriate for MRI contrast agents shows that administration of exogenous agents to the brain is achievable, but not without potential complications. BBB opening techniques incur side effects, and less disruptive trans-BBB delivery methods are probably not yet efficient enough to carry MRI-detectable quantities of imaging agents into the brain. For all of the delivery techniques, there is a clear advantage to minimizing the amount of contrast agent required for imaging, and where large quantities of contrast agent are required, pathological side effects related to the agents themselves may also be incurred. Many MRI contrast agents incorporate paramagnetic heavy metals such as gadolinium and manganese, which as bare ions are extremely toxic even at low concentrations. Dissociated Gd 3+ , for instance, inhibits calcium-dependent processes in cells (Cacheris et al., 1990) , and induces a nephrotoxicity syndrome at doses of about 0.3 mmol/kg (Kuo et al., 2007) . Chronic exposure to manganese is associated with neurological disorders (Olanow, 2004) , hepatic failure (Chandra and Shukla, 1976) , and cardiac toxicity (Wolf and Baum, 1983) , and Mn 2+ doses as low as 93 mg/kg for rats and 38 mg/kg for mice have been shown to cause serious adverse effects . SPIOs present a risk if iron escapes from nanoparticle cores (Longmire et al., 2008) ; chelation and additional treatments may be required in subjects where high doses of iron-containing contrast agents are used (Leite et al., 2002) . Molecular functions performed by MRI contrast agents may also induce disruptions. For instance, an MRI probe designed to target a cell surface receptor will almost certainly interfere with receptor transport and binding of the molecule by its natural ligands. Perhaps less obviously, a responsive MRI contrast agent that binds protons, ions, or other analytes will necessarily create buffering effects that disrupt normal physiology to an extent dependent on the concentration of the probe, as illustrated in Figure 2 . Such complications are common to almost all drugs and imaging agents, but are especially severe for MRI molecular imaging probes, because of the high concentrations required. There is therefore a particularly acute need to improve the sensitivity of MRI detection of molecular imaging agents.
V. APPROACHES TO IMPROVING MOLECULAR IMAGING SENSITIVITY
T 1 agents based on chelated heavy metals are the MRI contrast agents most commonly used in the clinic, and have been the basis for molecular imaging agents with potential applications in the nervous system (Jasanoff, 2007) . Clinically important complexes generally incorporate Gd 3+ and exhibit T 1 relaxivities (r 1 ) in the 3-5 mM −1 s −1 range at field strengths and temperatures typically used for research neuroimaging (B 0 ≥ 1.5 T) (Laurent et al., 2006) . In a biological sample with a background T 1 of 1 s, ~50 µM of an r 1 = 4 mM −1 s −1 complex would be required to produce a 20% signal change from background under strongly T 1 -weighted imaging conditions (spin echo repetition time TR = 100 ms). As the relaxivity of the agent increases, the concentration required for a given level of signal change decreases proportionately. Prospects for increasing the relaxivity of static and responsive T 1 agents have been discussed in the literature (Werner et al., 2008; Aime et al., 2009; Caravan et al., 2009; de Leon-Rodriguez et al., 2009 ). Basic approaches have involved tuning the molecular parameters that determine r 1 and incorporating paramagnetic atoms into polymeric, macromolecular, or nanoscale frameworks. For instance, in an example shown in Figure 3A , a Gd-hydroxypyridonate (Gd-HOPO)-based complex was designed to have water exchange rate, rotational correlation time, and number of inner sphere water molecules optimized for high field (>20 MHz) relaxivity, while still maintaining stability against Gd 3+ dissociation . The novel Gd-HOPO agent had an r 1 of 18 mM −1 s −1 (2.1 T, 25°C), roughly four times that of Gd-DTPA. The highest relaxivities reported at field strengths most commonly used for clinical imaging also include those of Gd-texaphyrin in 5% human serum albumin (r 1 = 21 mM −1 s −1 , 1 T, 37°C) (Geraldes et al., 1995) , a manganese analog of MS-325 in 660 µM rabbit serum albumin (r 1 = 32 mM −1 s −1 , 1.4 T, 37°C) (Troughton et al., 2004) , Gd-HOPO-based complexes conjugated to viral capsids (r 1 = 31 mM −1 s −1 , 1.5 T, 25°C) , and Gd-decorated single-wall carbon nanotubes (r 1 = 170 mM −1 s −1 , 1.5 T, 37°C) (Sitharaman and Wilson, 2006) . Although some of the reported high-relaxivity agents may be too unstable or large for in vivo imaging, improvements in the area nevertheless suggest that r 1 values far in excess of current workhorse contrast agents might be approached at moderate field strengths (0.5-3 T). At field strengths now favored for small animal imaging (≥4.7 T), gains in r 1 are also possible, but likely to be less pronounced (Werner et al., 2008; Aime et al., 2009; Caravan et al., 2009; de Leon-Rodriguez et al., 2009 ).
The exceptionally large magnetic moments of superparamagnetic materials have inspired efforts to use SPIOs and related nanoparticles as cellular or molecular imaging agents both inside and outside the brain. Monocrystalline or polycrystalline iron oxide cores, ranging from 3 to 300 nm in diameter, can be passivated with hydrophilic surface chemistry to yield T 2 contrast agents with relaxivities (r 2 ) generally in the range from 50 to 200 (mM Fe) −1 s −1 (Thorek et al., 2006; Sosnovik et al., 2008) . In T 2 -weighted imaging (spin echo time TE = 50 ms) with a background T 2 of 50 ms, an r 2 = 150 mM −1 s −1 SPIO colloid containing ~30 µM iron atoms (≪1 µM particles) would experience a 20% decrease in MRI signal from background. The fact that MRI signals are generally attenuated by SPIO agents has generally been considered to be a disadvantage, and has spawned a search for iron oxide-sensitive "positive contrast" techniques (Cunningham et al., 2005; Mani et al., 2006; Mills and Ahrens, 2009) . Although SPIO contrast agents produce contrast changes more effectively than typical T 1 agents (particularly at high B 0 ), they must still be used at concentrations several order of magnitudes above those required for PET; for brain imaging, delivery and physiological perturbations remain significant issues. Efforts to improve the relaxivity of SPIOs and other superparamagnetic agents are therefore also underway. High r 2 values have been measured with ferrite nanoparticles such as dimer-captosuccinic acid-solubilized MnFe 2 O 4 and CoFe 2 O 4 (r 2 = 228 and 393 mM −1 s −1 , respectively, at 9.4 T) (Lee et al., 2007; Kim et al., 2009) . Tuning properties of the water-solubilizing surface chemistry applied to SPIOs can also boost their relaxivity; for instance, one study reported an extraordinary r 2 of 910 mM −1 s −1 (7 T, 25°C) for 10 nm SPIO cores coated in a polyacrylamide matrix (Moffat et al., 2003) . In a further approach, micron-sized SPIOs with very high-total relaxivities have been used for MRI (Fig. 3B) . These microparticles have been reported to allow individual cells to be visualized and tracked in the living brain . Two alternatives to improving the relaxivity of conventional T 1 and T 2 MRI contrast agents are to use enzyme-based amplification strategies, and to employ imaging methods with reduced background signal. Enzymatic methods are exemplified by the demonstration approximately a decade ago that a T 1 agent sensitive to β-galactosidase, a commonly used reporter enzyme, could be constructed and used to map enzyme activity in whole frog embryos (Moats et al., 1997; Louie et al., 2000) . Additional approaches have targeted contrast agents to myeloperoxidase (Bogdanov et al., 2002) , tyrosinase (Weissleder et al., 1997) , and matrix metalloproteases (Harris et al., 2006; Lepage et al., 2007) . A related strategy noted earlier has been the use of metal transporters as genetic markers (Zurkiya et al., 2008; Goldhawk et al., 2009) ; amplification is produced because each protein can transport many paramagnetic metal ions.
As with imaging agents for other modalities, signal changes produced by MRI contrast agents may be difficult to detect either because they are small compared with scanner-related noise levels, or because of relatively high background from endogenous MRI signals, including physiological sources. The CEST technique provides one way to remove background influences, because the chemical shift of saturation can be varied to excite test or control proton pools (Sherry and Woods, 2008) . The chemical-shift dependence of CEST has allowed pH mapping and reporter gene detection in the brain, and facilitates creation of "ratiometric" CEST molecular imaging probes (Ward et al., 2000) , where analyte measurement does not depend on the concentration of the probe, as well as "multicolor" agents that can be imaged in parallel because they have different saturation frequencies . Although CEST contrast usually relies on long saturation times and millimolar concentrations of protons with chemical shifts resolved from water, it has been suggested that CEST agents that incorporate paramagnetic lanthanides could be detected at submicromolar levels (Zhang et al., 2003) ; improved sensitivity might also be achieved using superparamagnetic nanostructures as CESTlike agents (Zabow et al., 2008) . Heteronuclear imaging agents provide an alternative way to improve molecular imaging performance by minimizing background. 19 F is the most common isotope of fluorine and can be detected relatively efficiently by MRI, but is not present endogenously in the body. Both unresponsive and responsive 19 F probes have been synthesized (Yu et al., 2005a) , and 19 F imaging agents have been used recently in the brain in contexts where large local 19 F levels were obtainable and relatively low resolutions were used for scanning Porcari et al., 2008; Ruiz-Cabello et al., 2008) . In some cases, it is possible to synthesize fluorinated analogs of previously characterized compounds to produce MRI-detectable tracers with properties similar to the parent molecules; this approach was used in a recent demonstration of amyloid plaque detection by 19 F MRI (Fig. 3C) . Hyperpolarized 13 C agents can be constructed in similar fashion and may be imaged with no noticeable contribution from endogenous 13 C (Ardenkjaer-Larsen et al., 2003) , but currently only over periods on the order of a minute. Extending the utility of hyperpolarization-based molecular imaging may require nuclei with longer lasting polarization lifetimes (long T 1 ) (Dementyev et al., 2008) , or continuous polarization methods (Brunner et al., 1999; McCarney et al., 2007) . A sensitive technique for molecular imaging based on hyperpolarized 129 Xe gas and targeted Xe-binding cryptophane cages has also been proposed (Hilty et al., 2005; Schröder et al., 2006) , and may have interesting advantages.
VI. CONCLUSION
The unique capabilities of MRI for studying molecular processes in vivo were recognized early in the history of the technique, as was the potential utility of MRI contrast agents (Lauterbur, 1980) . In the intervening decades, a noteworthy effort has gone into design of imaging agents and approaches for detecting molecular targets in the nervous system. A number of MRI molecular neuroimaging approaches have now been reported to have met the requirements for brain delivery and sensitivity well enough to be validated in vivo. Recent improvements in MRI imaging agents and the methods required for them to access targets in the brain suggest that the list could be considerably expanded in the future. Although significant challenges remain, an MRI-based toolbox for relatively noninvasive molecular neuroimaging at the whole-brain level in animals could be within reach of today's technology. Ligand buffering by responsive contrast agents. A: The dynamics of a hypothetical ligand in the brain were simulated using a single compartment kinetic model (Helmchen and Tank, 2005) . In an approximation to neural signaling phenomena such as release and uptake of neurotransmitters or intracellular second messengers, a single pulse of 10 µM ligand was simulated at time 0.2 s, followed by a process that removed ligand at a rate of 20 s −1 on a background of weak endogenous buffering (buffer concentration 1 µM, K d = 1 µM). The graph shows time courses of free (unbound) ligand in the presence of 0 µM (solid line), 5 µM (dashed line), or 30 µM (dotted line) of a responsive T 1 contrast agent assumed to bind the ligand with a dissociation constant of 1 µM. The simulation shows that the peak amount of free ligand, and its rate of decay back to baseline, are diminished by increasing contrast agent concentrations. The inset shows partial saturation of the contrast agent as a function of time for 5 and 30 µM concentrations. B: Peak T 1 -weighted MRI signal changes were computed from the fractional saturation curves of panel (A), assuming background T 1 = 1 s, TR = 0.2 s, and ligand-induced relaxivity change from 0 to 10 mM −1 s −1 . A greater ligand-dependent signal change is observed in the presence of 30 µM contrast agent (CA), which also buffered the ligand more severely.
